Socrate 2.0 presentation



The SOCRATE 2.0 program covers three areas of research involving the integration of basic with translational and clinical research as well as social sciences and epidemiology on the same localisation at Gustave Roussy Cancer Center. Every work-packages are led by a mix of clinicians and biologists : the SOCRATE 2.0 project aims at breaking barriers between clinical and basic research. This innovative structuration has the ambition to boost the emergence of new treatments for cancer patients in an unprecedented time scale


Scientific Work-Packages:


fleche-vert-droite-9x9 WP 1
DNA Damage Response

Scientific coordinators:
Patricia Kannouche & Sophie Postel-Vinay


To ensure the integrity of the genome and hence the fitness and viability of cells, DNA lesions that are formed as a result of various toxic assaults are normally repaired by an elaborate network of DNA damage response (DDR) pathways. Interestingly, DNA is also the main target of most chemotherapeutic agents and ionizing radiations, two key components of anti-cancer therapy. Gustave Roussy has contributed to elucidating DNA repair pathways and their abnormalities for over 30 years. SOCRATE 2.0 will focus on better understanding the crosstalk between DNA damage, DNA damage response pathways, inflammation and immunity. We plan to accumulate the scientific knowledge necessary to design new diagnostic, prognostic, and therapeutic strategies for chemotherapy, radiotherapy, and DNA damage/DDR- associated targeted therapies.

fleche-vert-droite-9x9 WP 2
Immuno-Oncology and Tumor Micro-environment

Scientific coordinators:
Laurence Zitvogel & Jean-Yves Scoazec

Aims :

The discovery of cancer immune checkpoints and the successes of immune- and tumor -targeted antibodies have changed the landscape of the clinical management of various malignancies. The hallmarks of oncogenesis are now encompassing inflammation and immunosuppression. Teams from SOCRATE 2.0 have a long lasting commitment to immunology with key contributions to decipher new concepts (immunogenic cell death, resistance to immune modulation, tumor antigens, immunosurveillance, monoclonal antibodies therapy). Future challenges rely on understanding mechanisms to circumvent the primary and secondary resistances to immune attacks in order to exploit and foster the numerous clinically relevant next generation trials combining conventional-, tumor targeted- and immune-targeted -therapies.


fleche-vert-droite-9x9 WP 3
Cancer Molecular Dynamics, Social Sciences and Epidemiology

Scientific coordinators:
Olivier Benard, Fabrice André & Ines Vaz-Luis


Molecular medicine also called precision or personalized medicine is a scientific approach based on molecular analyses that drive methods for early diagnosis, and guidance for targeted therapies. The SOCRATE 2.0 program aims at identifying targets, validating the molecular-driven therapeutic strategies and studying mechanisms of clonal evolution in hematologic malignancies and solid tumors. The long-term vision is to propose an extensive molecular analysis to each patient with difficult-to-treat cancer in order to propose a personalized therapy. In addition, we will also explore (i) how evolution of innovative cancer therapies triggers specific social issues (Sylvain Besle) and (ii) how cancer treatments-elicited side effects affect survivorship and return to work (Ines Vaz-Luis).